Rafael Amado
2017 - Adaptimmune Therapeutics
In 2017, Rafael Amado earned a total compensation of $1.5M as Chief Medical Officer at Adaptimmune Therapeutics, a 24% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $199,305 |
|---|---|
| Option Awards | $849,927 |
| Salary | $442,900 |
| Other | $43,037 |
| Total | $1,535,169 |
Amado received $849.9K in option awards, accounting for 55% of the total pay in 2017.
Amado also received $199.3K in non-equity incentive plan, $442.9K in salary and $43K in other compensation.
Rankings
In 2017, Rafael Amado's compensation ranked 6,851st out of 14,666 executives tracked by ExecPay. In other words, Amado earned more than 53.3% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 6,851 out of 14,666 | 53rd |
Division Manufacturing | 2,539 out of 5,772 | 56th |
Major group Chemicals And Allied Products | 822 out of 2,075 | 60th |
Industry group Drugs | 636 out of 1,731 | 63rd |
Industry Biological Products, Except Diagnostic Substances | 116 out of 313 | 63rd |
Source: SEC filing on April 27, 2018.
Amado's colleagues
We found four more compensation records of executives who worked with Rafael Amado at Adaptimmune Therapeutics in 2017.
News
Allogene Therapeutics CEO David Chang's 2021 pay jumps 30% to $10M
April 26, 2022
Allogene Therapeutics CEO David Chang's 2020 pay falls 30% to $7.8M
April 22, 2021
Allogene Therapeutics CEO David Chang's 2019 pay slips 13% to $11M
April 23, 2020
Adaptimmune Therapeutics CEO James Noble's 2018 pay jumps 58% to $2.6M
March 15, 2019